MX2024001211A - Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de tipos de cancer de sangre. - Google Patents
Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de tipos de cancer de sangre.Info
- Publication number
- MX2024001211A MX2024001211A MX2024001211A MX2024001211A MX2024001211A MX 2024001211 A MX2024001211 A MX 2024001211A MX 2024001211 A MX2024001211 A MX 2024001211A MX 2024001211 A MX2024001211 A MX 2024001211A MX 2024001211 A MX2024001211 A MX 2024001211A
- Authority
- MX
- Mexico
- Prior art keywords
- heterodimeric
- treatment
- fusion proteins
- blood cancers
- il15r alpha
- Prior art date
Links
- 201000005787 hematologic cancer Diseases 0.000 title abstract 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 title abstract 2
- 108091006020 Fc-tagged proteins Proteins 0.000 title 1
- 101150039708 IL15 gene Proteins 0.000 title 1
- 230000004927 fusion Effects 0.000 abstract 2
- 239000000178 monomer Substances 0.000 abstract 2
- 102000003812 Interleukin-15 Human genes 0.000 abstract 1
- 108090000172 Interleukin-15 Proteins 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación proporciona métodos para tratar cáncer de sangre, tal como mieloma múltiple mediante la administración de una proteína heterodimérica que comprende un primer monómero que comprende una fusión de proteína IL15 y dominio Fc, y un segundo monómero que comprende una fusión de proteína IL15Ra y dominio Fc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163226359P | 2021-07-28 | 2021-07-28 | |
| PCT/US2022/074179 WO2023010031A1 (en) | 2021-07-28 | 2022-07-27 | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001211A true MX2024001211A (es) | 2024-02-12 |
Family
ID=83004757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001211A MX2024001211A (es) | 2021-07-28 | 2022-07-27 | Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de tipos de cancer de sangre. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4376869A1 (es) |
| JP (1) | JP2024527047A (es) |
| KR (1) | KR20240042442A (es) |
| CN (1) | CN118382450A (es) |
| AU (1) | AU2022320793A1 (es) |
| CA (1) | CA3225405A1 (es) |
| IL (1) | IL310372A (es) |
| MX (1) | MX2024001211A (es) |
| WO (1) | WO2023010031A1 (es) |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| WO1998048032A2 (en) | 1997-04-21 | 1998-10-29 | Donlar Corporation | POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
| US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
| EP1490677A4 (en) | 2002-02-27 | 2006-01-18 | California Inst Of Techn | COMPUTER METHOD FOR DESIGNING ENZYMES FOR THE INCORPORATION OF AMINO ACID ANALOGUES INTO PROTEINS |
| US7230068B2 (en) | 2003-10-09 | 2007-06-12 | Ambrx, Inc. | Polymer derivatives |
| BRPI0507159A (pt) | 2004-02-02 | 2007-06-26 | Ambrx Inc | polipeptìdeos em feixe de quatro hélices humanos modificados e seus usos |
| CA2555185C (en) | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
| NZ561883A (en) | 2005-03-23 | 2010-11-26 | Genmab As | Antibodies against CD38 for treatment of multiple myeloma |
| CA2625681C (en) | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US7713937B2 (en) | 2006-11-10 | 2010-05-11 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| DE102010054016A1 (de) | 2010-12-10 | 2012-06-14 | Ziemek Cable Technology Gmbh | Verfahren zum Verbinden eines Aluminiumbandes mit einem Kupferband |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| CA2961439A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| JP7142630B2 (ja) | 2016-10-14 | 2022-09-27 | ゼンコア インコーポレイテッド | ＩＬ１５／ＩＬ１５Ｒαヘテロ二量体ＦＣ－融合タンパク質 |
| JP7526099B2 (ja) | 2018-03-28 | 2024-07-31 | 武田薬品工業株式会社 | 抗ｃｄ３８抗体の皮下投薬 |
| CA3097741A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| SG11202010159RA (en) * | 2018-04-18 | 2020-11-27 | Xencor Inc | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| KR20220020879A (ko) * | 2019-06-12 | 2022-02-21 | 에스크진 파마, 아이엔씨. | 새로운 il-15 프로드럭 및 이를 사용하는 방법 |
| AU2021213767A1 (en) * | 2020-01-28 | 2022-07-28 | Genentech, Inc. | IL15/IL15R alpha heterodimeric Fc-fusion proteins for the treatment of cancer |
-
2022
- 2022-07-27 CA CA3225405A patent/CA3225405A1/en active Pending
- 2022-07-27 KR KR1020247004603A patent/KR20240042442A/ko unknown
- 2022-07-27 WO PCT/US2022/074179 patent/WO2023010031A1/en active Application Filing
- 2022-07-27 MX MX2024001211A patent/MX2024001211A/es unknown
- 2022-07-27 JP JP2024504956A patent/JP2024527047A/ja active Pending
- 2022-07-27 EP EP22757795.4A patent/EP4376869A1/en active Pending
- 2022-07-27 AU AU2022320793A patent/AU2022320793A1/en active Pending
- 2022-07-27 CN CN202280064078.2A patent/CN118382450A/zh active Pending
- 2022-07-27 IL IL310372A patent/IL310372A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022320793A1 (en) | 2024-02-01 |
| IL310372A (en) | 2024-03-01 |
| KR20240042442A (ko) | 2024-04-02 |
| WO2023010031A1 (en) | 2023-02-02 |
| EP4376869A1 (en) | 2024-06-05 |
| CN118382450A (zh) | 2024-07-23 |
| JP2024527047A (ja) | 2024-07-19 |
| CA3225405A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009100A (es) | Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer. | |
| PH12019502621A1 (en) | Antibody-cytokine engrafted proteins and methods of use in the treatement of cancer | |
| WO2020072821A3 (en) | Il-12 heterodimeric fc-fusion proteins | |
| MX2019004692A (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos. | |
| WO2021007428A3 (en) | Molecules, compositions and methods for treatment of cancer | |
| PE20180120A1 (es) | Proteinas de union a icos | |
| MX2022003930A (es) | Conjugados de péptido de camptotecina. | |
| EP4249064A3 (en) | Novel fusion protein specific for cd137 and pd-l1 | |
| MX2021008958A (es) | Proteínas de unión a antígeno del receptor gamma anti-il2. | |
| MX2021002208A (es) | Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80. | |
| ZA202202363B (en) | Antibodies against ilt2 and use thereof | |
| MX2021010061A (es) | Proteínas de fusión fc con dominio extracelular de cd80 para tratar tumores negativos para pd-l1. | |
| CR20220076A (es) | Anticuerpos anti-cd96 y sus métodos de uso | |
| CL2020003355A1 (es) | Proteínas inmunodominantes y fragmentos en esclerosis múltiple | |
| WO2021181233A3 (en) | Cd80-fc fusion protein and uses thereof | |
| PH12020551955A1 (en) | Anti-cd63 antibodies, conjugates, and uses thereof | |
| BR112023021665A2 (pt) | Método para tratar um câncer, e, composição | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MX2023013912A (es) | Metodos para inhibir ras. | |
| WO2020180712A8 (en) | Anti-tnfr2 antibodies and uses thereof | |
| MX2021008716A (es) | Metodo para tratar dolor de osteoartritis al administrar resiniferatoxina. | |
| WO2022034524A3 (en) | Antibodies against ilt2 and use thereof | |
| MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
| EA202090558A1 (ru) | Схемы лечения | |
| BR112021016923A2 (pt) | Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits |